Clinical trials: Aspirin
Body Weight
Body Weight, Aspirin Dose and Pro-resolving Mediators
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
- Trial name
- NCT04697719
- Testing
- Aspirin 81mg, Aspirin 325mg
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Barrett Esophagus, Esophageal Adenocarcinoma
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
This randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation.
- Trial name
- NCT02521285
- Testing
- Aspirin, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 10 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Node Positive HER2 Negative Breast Cancer
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy…
- Trial name
- NCT02927249
- Testing
- Aspirin
- Where
- 1,452 sites in United States, Canada and 2 more
- Volunteers
- 3,021 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Adenoma, Colorectal Carcinoma
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT02965703
- Testing
- Aspirin, Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hairy Cell Leukemia
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Background: Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells.
- Trial name
- NCT03805932
- Testing
- Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: Low Dose Aspirin
- Trial name
- NCT05056896
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Massachusetts General Hospital
Tuberculosis, Pulmonary, Tuberculosis, MDR
Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
The purpose of this study is to assess the efficacy and safety of 2 repurposed drugs (acetylsalicylic acid and ibuprofen), for use as adjunct therapy added to, and compared with, the standard of care (SoC) WHO-recommended TB…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, MDR, Tuberculosis Infection
- Trial name
- SMA-TB (NCT04575519)
- Testing
- Control group, ASA group, IBU group
- Where
- 3 sites in Georgia, South Africa
- Volunteers
- 426 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Rheumatoid Arthritis, Cardiovascular Diseases
NSAIDs vs. Coxibs in the Presence of Aspirin
The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial…
- Trial name
- NCT03699293
- Testing
- celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Platelet and Thrombosis Research, LLC
COPD, Emphysema
Anti-Platelets in Chronic Obstructive Pulmonary Disease
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e.
- Conditions
- COPD, Emphysema, Emphysema or COPD
- Trial name
- NCT05567562
- Testing
- dual anti-platelet therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Colorectal Cancer
Adjuvant Low Dose Aspirin in Colorectal Cancer
ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer.
- Trial name
- ALASCCA (NCT02647099)
- Testing
- Acetylsalicylic acid
- Where
- 32 sites in Denmark, Finland and 2 more
- Volunteers
- 626 people
- Sponsor
- Anna Martling
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Coronary Syndrome
WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
The trial is a pharmacodynamic study to determine the effect of a novel regimen of aspirin 20 mg BD plus rivaroxaban 2.5 mg BD on haemostasis, fibrin clot dynamics, inflammatory markers, platelet function and arachidonic acid…
- Trial name
- WILLOW CCS (NCT04990791)
- Testing
- Aspirin 75mg, Aspirin 20mg, Rivaroxaban 2.5 mg
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Myocardial Infarction, Arthritis
Mechanisms of Action of Acetaminophen
This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen.
- Trial name
- NCT00646906
- Testing
- Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hyperlipidemia
Biosynthesis of PGD2 in Vivo
The investigator would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin. Phase I: Subjects were assigned to either placebo or aspirin groups.
- Trial name
- NCT01275300
- Testing
- Aspirin, Niacin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Colorectal Cancer
ASPirin Intervention for the REDuction of Colorectal Cancer Risk
This research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer
- Trial name
- ASPIRED (NCT02394769)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Massachusetts General Hospital
Polycythemia Vera (PV)
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
This is a Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.
- Trial name
- NCT04182100
- Testing
- P1101, Low-dose aspirin, Phlebotomy
- Where
- 8 sites in Japan
- Volunteers
- 29 people
- Sponsor
- PharmaEssentia Japan K.K.
Acute Coronary Syndrome
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Heart attacks are usually caused by clots in a coronary artery, depriving the heart muscle of blood. Platelets are the main type of blood cell causing clots to form and physicians typically give a combination of two anti-platelet…
- Trial name
- WILLOW TREE (NCT03869268)
- Testing
- Aspirin, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Pre-Eclampsia
Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia
Endothelial dysfunction and defective placental vascularization are hypothesized to be significant causes of preeclampsia. In preeclampsia, due to vascular endothelial dysfunction, vasoconstriction and platelet activation can…
- Trial name
- ASPERIN (NCT03893630)
- Testing
- Acetylsalicylic Acid 81 mg, Acetylsalicylic Acid 162 mg, Control
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- John O'Brien, MD
Blood Pressure
Postpartum ASA and NT-proBNP
This study is a double-blinded randomized-controlled trial in which patients will be randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum.
- Trial name
- NCT05889468
- Testing
- Aspirin 81Mg Ec Tab
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Duke University